Drugs /

tumor treating fields therapy

Back to Drugs List

Overview

Trade Name(s):
Optune
NCI Definition [1]:
A type of electromagnetic field therapy that uses low-intensity, intermediate-frequency alternating electrical fields to a target area to induce selective toxicity to proliferating cells.

Clinical Trials

View Clinical Trials for tumor treating fields therapy

Tumor treating fields therapy has been investigated in 12 clinical trials, of which 8 are open and 4 are closed. Of the trials investigating tumor treating fields therapy, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open).

EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for tumor treating fields therapy clinical trials.

Glioblastoma, astrocytoma, and non-small cell lung carcinoma are the most common diseases being investigated in tumor treating fields therapy clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tumor Treating Fields Therapy
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Tumor Treating Fields Therapy
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tumor treating fields therapy and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
alternating electric field therapy, ttf, ttfields, Optune, tumor treating fields
NCIT ID [1]:
C146882

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.